Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Punnoose

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
The New England Journal of Medicine|March 22, 2018
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic LeukemiaJohn F Seymour, Thomas J Kipps, Barbara Eichhorst, et al.
Molecular Cancer Therapeutics|March 5, 2016
Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma ModelsElizabeth A Punnoose, Joel D Leverson, Franklin Peale, et al.
Blood|August 30, 2017
Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MMPhilippe Moreau, Asher Chanan-Khan, Andrew W Roberts, et al.
Blood|October 12, 2017
Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myelomaShaji Kumar, Jonathan L Kaufman, Cristina Gasparetto, et al.
The Lancet. Oncology|November 1, 2020
Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trialShaji K Kumar, Simon J Harrison, Michele Cavo, et al.
Blood|August 14, 2020
Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphomaPier Luigi Zinzani, Ian W Flinn, Sam L S Yuen, et al.
British Journal of Cancer|September 18, 2015
PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patientsElizabeth A Punnoose, Roberta Ferraldeschi, Edith Szafer-Glusman, et al.
Journal of Translational Medicine|July 4, 2012
Considerations in the development of circulating tumor cell technology for clinical useDavid R Parkinson, Nicholas Dracopoli, Brenda Gumbs Petty, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
The New England Journal of Medicine|March 22, 2018
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic LeukemiaJohn F Seymour, Thomas J Kipps, Barbara Eichhorst, et al.
Molecular Cancer Therapeutics|March 5, 2016
Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma ModelsElizabeth A Punnoose, Joel D Leverson, Franklin Peale, et al.
Blood|August 30, 2017
Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MMPhilippe Moreau, Asher Chanan-Khan, Andrew W Roberts, et al.
Blood|October 12, 2017
Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myelomaShaji Kumar, Jonathan L Kaufman, Cristina Gasparetto, et al.
The Lancet. Oncology|November 1, 2020
Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trialShaji K Kumar, Simon J Harrison, Michele Cavo, et al.
Blood|August 14, 2020
Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphomaPier Luigi Zinzani, Ian W Flinn, Sam L S Yuen, et al.
British Journal of Cancer|September 18, 2015
PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patientsElizabeth A Punnoose, Roberta Ferraldeschi, Edith Szafer-Glusman, et al.
Journal of Translational Medicine|July 4, 2012
Considerations in the development of circulating tumor cell technology for clinical useDavid R Parkinson, Nicholas Dracopoli, Brenda Gumbs Petty, et al.
Pageof 3